SS-31 vs MOTS-c: Mitochondrial Peptide Comparison

What is the core difference between SS-31 and MOTS-c?

SS-31 stabilizes mitochondrial structure by binding cardiolipin, while MOTS-c acts as a metabolic signal by activating AMPK.

SS-31, also called elamipretide, is a small synthetic peptide that concentrates in the inner mitochondrial membrane and binds cardiolipin, a lipid that organizes the proteins of the electron transport chain (Chavez et al., 2020). By keeping cardiolipin and its protein partners in order, SS-31 helps the chain move electrons efficiently and reduces the leak of reactive oxygen species (Chavez et al., 2020).

MOTS-c takes a completely different route. It is a peptide encoded within mitochondrial DNA, a mitochondrial-derived peptide, and it acts more like a hormone-style signal. In research, MOTS-c activated AMP-activated protein kinase (AMPK), a master sensor of cellular energy, which shifted metabolism toward glucose use and improved insulin sensitivity in mouse models (Lee et al., 2015).

So one peptide is a structural stabilizer and the other is a signaling molecule. That single distinction drives most of the differences below.

Which one has stronger human evidence?

SS-31 has the stronger human evidence, with a completed randomized clinical trial and a 2025 FDA accelerated approval for a rare mitochondrial disease, while MOTS-c remains largely preclinical.

SS-31 has moved through controlled human research. In the TAZPOWER study, a phase 2/3 randomized trial followed by an open-label extension, elamipretide was tested in patients with Barth syndrome, a rare X-linked mitochondrial condition caused by tafazzin mutations that impair cardiolipin remodeling; the open-label extension was associated with improvements in skeletal muscle performance and patient-reported fatigue (Reid Thompson et al., 2021). Building on that record, the FDA granted accelerated approval to elamipretide HCl (Forzinity) to improve muscle strength in adult and pediatric Barth syndrome patients weighing at least 30 kg in September 2025 (FDA, 2025). That places it far ahead of most mitochondrial peptides on the evidence ladder, though the approval is narrow and specific to Barth syndrome, not a general-use clearance.

MOTS-c, by contrast, is defined mostly by mechanism work in cells and animals. The foundational study demonstrated AMPK activation and metabolic effects in mice, not in large human trials (Lee et al., 2015). Human data on MOTS-c is limited, so any claims about human outcomes extrapolate from animal work.

SS-31 vs MOTS-c decision table

The table below sets the two side by side. Dose figures are described only where a named source reports them, and none of this is guidance.

How do their mechanisms actually differ inside the cell?

SS-31 protects the physical assembly of energy-producing proteins, while MOTS-c changes the instructions cells follow about energy use.

Think of the mitochondrion as a factory. SS-31 keeps the factory floor organized. By binding cardiolipin, it holds the electron transport chain complexes in the right arrangement so they pass electrons cleanly and waste less energy as damaging oxidants (Chavez et al., 2020). The benefit is structural: a better-maintained machine.

MOTS-c changes the management memo. Activating AMPK tells the cell that energy is scarce and it should burn glucose more readily and improve insulin response, which is what researchers observed in mouse metabolic models (Lee et al., 2015). The benefit is regulatory: a shift in how energy is handled.

Because the two act at different levels, structure versus signaling, they are not interchangeable and are not the same tool for the same job.

What about side effects and safety signals?

SS-31 has been studied in humans with monitored safety data from trials, while MOTS-c safety in humans is not well characterized because most work is preclinical.

SS-31 was evaluated in a controlled trial that tracked tolerability alongside function (Reid Thompson et al., 2021), and its 2025 accelerated approval required a reviewed safety and efficacy package (FDA, 2025). That does not make it a general-use compound, and its studied use is narrow and disease-specific.

MOTS-c has not completed the same human safety program. The primary evidence base is animal and cell work (Lee et al., 2015), so human tolerability, long-term effects, and interactions are not established. When human data is this limited, unknowns should be treated as real.

For either compound, a qualified clinician is the correct source for any personal decision. Nothing here recommends use, dose, timing, or route.

Which should a researcher read about next?

Choose based on the question you are asking: structural mitochondrial protection points to SS-31, and metabolic AMPK signaling points to MOTS-c.

If your interest sits with AMPK activation, glucose handling, and the mitochondrial-derived peptide category, the MOTS-c guide goes deeper on mechanism and the current evidence limits. If your interest is cardiolipin biology and the electron transport chain, SS-31 and the Chavez et al., 2020 findings are the anchor.